Project Grant R37CA304094
Award Date 8/26/25
Completion Date 7/31/30
Dollars Obligated $678K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the University of California, San Francisco (UCSF) to genetically engineer myeloid cells, including macrophages and dendritic cells, for the treatment of solid tumors. The $0.00 award, with a project period from August 1, 2025 to July 31, 2028, aims to apply advanced genetic engineering tools to reprogram myeloid cells and enhance their tumoricidal activities and resistance to...
- This federal Project Grant award of $640,522 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Leland Stanford Junior University supports research to elucidate how microbial microproteins modulate macrophage function, a critical coordinator of tumor immune response. The project aims to carry out high-throughput screens of thousands of microbial macromolecules to identify those that directly modulate macrophages, with the goal of enhancing cancer immunotherapy...
- This federal Project Grant award of $680,598 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research to understand the role of the Cullin-5 complex in regulating T cell dysfunction in cancer. The research aims to develop new therapeutic approaches to engineer T cells with durable effector function, by targeting the Cullin-5 complex to prevent T cell dysfunction caused by chronic tumor antigen stimulation. The award was provided to the...
- This federal Project Grant award of $663,340 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to elucidate the mechanisms by which the ablation of intratumoral regulatory T cells can mobilize NK cells and CD4 T cells to control MHC I-deficient tumors. The research aims to determine how CD4 T cell help enhances the antitumor function of NK cells, including the role of cytokines like IL-2 and IL-15, as well as test whether intratumoral Treg depletion...
- This $156,276 federal Project Grant award was provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program. The funding supports research aimed at decoding therapeutic tumor antigens and understanding how dendritic cells contribute to anti-tumor T cell immunity, with a focus on pancreatic cancer. Key objectives include comparing tumor immunopeptidomes presented by cancer cells versus dendritic cells, and evaluating the impact of regulatory T cells on...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $676,006 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at early identification of resistance to immunotherapy for cancer treatment. The key products and services to be delivered under this 5-year award include: Developing and testing non-invasive imaging strategies, such as PET scans and implantable fluorescence sensors,...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $282,053 to The Regents of the University of California, San Francisco (UCSF) to support research aimed at understanding how liver disease impacts myeloid cells and drives immunotherapy resistance in hepatocellular carcinoma. The 5-year award, starting on March 1, 2025, will fund experiments to examine immunosuppressive myeloid cells in viral and non-viral hepatitis, use...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $101,340.00 to the Regents of the University of Michigan to conduct research focused on understanding the role of the MS4A14 protein in regulating macrophage activation and its impact on anti-tumor immunity. The award period runs from Dec 12, 2025 to Jun 16, 2028. The research aims to investigate how MS4A14 expression in macrophages influences their ability to present antigens and...
- The National Institutes of Health (NIH) National Cancer Institute awarded a $618,928 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of California, Berkeley. The 5-year grant, awarded on June 9, 2025, will fund research to investigate the mechanisms by which regulatory T cells (Tregs) within tumors suppress antitumor immune responses. The project aims to determine if blocking Treg function solely within the tumor microenvironment is sufficient to control...